There is an urgent need for effective therapies against the novel COVID-19 virus. Studies have shown that amiodarone and verapamil can interfere with coronavirus entry and amplification by blocking ion channels. ReCOVery-SIRIO is a randomized study to investigate amiodarone or verapamil compared with usual care in symptomatic patients hospitalized with confirmed COVID-19 infection.
Drug: Amiodarone
Ion channel blocker
Drug: Verapamil
Ion channel blocker
Inclusion Criteria:
Hospitalized patients with confirmed COVID-19 infection and symptoms, with an oxygenation
index defined as quotient of partial pressure of oxygen in arterial blood (PaO2, in mmHg)
and fraction of inspired oxygen (FiO2) > 200.
Exclusion Criteria:
- Acute respiratory distress syndrome (ARDS)
- Contraindications for or known hypersensitivity to amiodarone or calcium channel
blockers
- Long QT syndrome
- Prolonged baseline QTc interval (≥450 ms).
- Cardiogenic shock or severe hypotension (SBP< 90 mmHg)
- Severe left ventricle dysfunction (left ventricular ejection fraction ≤35%)
- Severe sinus - node dysfunction with marked sinus bradycardia
- 2nd/3rd degree heart block
- Bradycardia without pacemaker that has caused syncope
- History of severe dysthyroidism
- A-Fib/flutter conducted via accessory pathway (ie,Wolff -Parkinson-White)
Nicolaus Copernicus University
Bydgoszcz, Poland